Oragenics : Positive Clinical Results for its Proprietary Weight Loss Agent, LPT3-04

February 14, 2012 - Oragenics, Inc. (OTCBB:ORNI) announced that a recently completed randomized, double-blind, placebo-controlled, human clinical study with 32 enrolled subjects resulted in a statistically and clinically significant reduction in body weight when healthy, overweight and mildly obese adult volunteers were given daily supplementation of Oragenics’ Weight Loss Agent LPT3-04 over a twelve-week period. This study, sponsored by Oragenics, was conducted at the Miami Research Associates (MRA) clinical research facilities in Miami, Florida. MRA investigators also confirmed that there were no safety concerns with daily supplementation of LPT3-04 over the 12-week duration of the trial, and that no reports of serious adverse events, including depression, occurred during this trial. This human study result confirms the extensive results obtained from animal safety and efficacy studies completed to date by Oragenics, and suggests that LPT3-04, a natural occurring dietary substance with an excellent safety and tolerance profile, can support weight loss in overweight men and women.

The World Health Organization estimated that by 2015, there will be more than 1.5 billion overweight consumers. Further, according to a 2012 healthcare market research report published by Markets and Markets, the total global weight loss market is expected to be worth US$586.3 billion by 2014, with a compound annual growth rate of 10.9% from 2009 to 2014. These reports suggest that the opportunities for a scientifically-substantiated weight management product are impressive...[PDF] Oragenics' Press Release -

Hanmi : license agreement for a new anti-obesity botanical drug

16, Feb. 2012 - Hanmi pharmaceuticals announced that it has entered into a licensing agreement with AngioLab for a new anti-obesity botanical drug, ALS-L1023.

ALS-L1023 is a Melissa leaf (Lemon Balm) ethyl acetate dried extract, having excellent angiogenesis and MMP inhibitory activities. The inhibition of angiogenesis in the growing adipose tissue is a novel approach for the prevention and treatment of obesity having a high specificity to visceral fat (intra-abdominal fat).

A randomized, double-blind, placebo-controlled, phase II human trial was completed in ASAN Medical Center and Inje University Seoul Paik Hospital. The statistically significant reduction of visceral fat by 15% was observed in comparison with the baseline after 12 weeks. In safety assessment, there was no statistically significant Adverse Events. Furthermore, plasma adiponectin level has increased, while plasma free fatty acid level has decreased... Hanmi pharmaceuticals' Press Release -